Reported Sunday, Natera Will Unveil SAGITTARIUS Phase III Data At ESMO 2026 Showing Signatera Results Changed Treatment Plans For One In Three Colon Cancer Patients, Of Which 87% De-Escalated On MRD Negativity

Loading news article.

Reported Sunday, Natera Will Unveil SAGITTARIUS Phase III Data At ESMO 2026 Showing Signatera Results Changed Treatment Plans For One In Three Colon Cancer Patients, Of Which 87% De-Escalated On MRD Negativity | WAPE

Reported Sunday, Natera Will Unveil SAGITTARIUS Phase III Data At ESMO 2026 Showing Signatera Results Changed Treatment Plans For One In Three Colon Cancer Patients, Of Which 87% De-Escalated On MRD Negativity

Article summary

Related companies

Comments —